Search

Your search keyword '"Calistri, E."' showing total 102 results

Search Constraints

Start Over You searched for: Author "Calistri, E." Remove constraint Author: "Calistri, E."
102 results on '"Calistri, E."'

Search Results

1. Differences among young adults, adults and elderly chronic myeloid leukemia patients

6. Differences among young adults, adults and elderly chronic myeloid leukemia patients

10. S123 SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED

11. PB1930 CORRELATION BETWEEN LEVELS OF EARLY MOLECULAR RESPONSE AND BCR-ABL TRANSCRIPT TYPE IN STABLE DMR ATTAINMENT IN CML PATIENTS TREATED WITH IMATINIB

12. ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY

13. LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE

14. EP-1129: Perfusion CT in the evaluation of Nodal response after RCT in H&N cancers: a prospective study

15. Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML

16. BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC

17. Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure

18. VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY?

19. Molecular 'warning' CML patients: a retrospective study of Gruppo Triveneto LMC

21. VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY?

22. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

24. BACK TO LIFE -LIVING, TREATING, MANAGING MYELOFIBROSIS: THE BURDEN OF ILLNESS FOR PATIENTS AND THEIR FAMILIES

29. Conventional unrelated boine marrow transplantation for patients with haematological disease: probability of finding a donor and outcome of 131 consecutivecases in a single centre

33. Imatinib-treated Chronic Myeloid Leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response

34. Multicenter prospective clinical trial with low dose Gentuzumab-Ozogamicin plus fludarabine, Cytarabine, Idarubicin, (GO.FLAI) as induction therapy of CD33-positiveacute myeloid leukemia AML patients younger than 65 years

35. MULTICENTER PROSPECTIVE CLINICAL TRIAL WITH LOW DOSE GEMTUZUMAB-OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN (GO-FLAI) AS INDUCTION THERAPY OF CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS YOUNGER THAN 65 YEARS

44. Characterization of Gypsophila species and commercial hybrids with nuclear whole-genome and cytoplasmic molecular markers.

48. Early Versus Late Postoperative Radiotherapy in Patients With Prostate Cancer: Results of a Single-centre Retrospective Study

49. Differences among young adults, adults and elderly chronic myeloid leukemia patients

50. Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools

Catalog

Books, media, physical & digital resources